New research sets path forward for long COVID tests, treatments
The latest research on long COVID, includes biomarkers and paves a path for potential tests and treatments.
Source: beckershospitalreview.com
Complement System News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Complement System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Complement System Today - Breaking & Trending Today
Origins of Cell Damage in Long COVID Uncovered
In persistent long COVID, elevated blood levels signal damage to various cells—red blood cells, platelets, and blood vessels.
Source: medindia.net
With More 2024 FDA Filings Planned, Novartis Drug Starts Showing Blockbuster Potential
Novartis drug iptacopan, which won its first FDA approval in early December in a rare blood disorder, has met the main goal of a pivotal test in an ultra-rare kidney disease. The small molecule’s potential to address many diseases has stirred up blockbuster expectations.
Source: medcitynews.com
Novartis Nabs FDA Nod for Rare Disease Drug Rival to AstraZeneca Meds
FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.
Source: medcitynews.com
Unmet Needs In Managing IgAN
Chee Kay Cheung, MBCHB, MRCP, PhD, discusses unmet needs in the management of IgAN, commenting on the need for new medication and highlighting budesonide and SGLT2 inhibitors.
Source: hcplive.com